XLO — XILIO THERAPEUTICS INC

Ownership history in GILEAD SCIENCES, INC.  ·  5 quarters on record

This page tracks every 13F SEC filing in which GILEAD SCIENCES, INC. reported a position in XILIO THERAPEUTICS INC (XLO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.56% (2024 Q4)
Avg. % of fund
0.47%
First filed
2024 Q4
Last filed
2025 Q4
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 9,105,451 — 0% 0.30% $5.8M $8.96
2025 Q3 UNCHANGED 9,105,451 — 0% 0.43% $7.7M $11.80
2025 Q2 UNCHANGED 9,105,451 — 0% 0.48% $6.19B $9.52
2025 Q1 UNCHANGED 9,105,451 — 0% 0.56% $6.60B $10.14
1 older quarter hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    XLO price (monthly, adj. close)

Other funds also holding XLO

As of 2025 Q4 — sorted by position size

Bain Capital Life Sciences Investors, LLC 3Y 7Y 0.36% STEMPOINT CAPITAL LP 0.22% Sio Capital Management, LLC 3Y 7Y 0.21% Frazier Life Sciences Management, L.P. 3Y 0.1% Velan Capital Investment Management LP 3Y 0.06% Stonepine Capital Management, LLC 3Y 7Y 0.06% Ghisallo Capital Management LLC 3Y 0.03% GSA CAPITAL PARTNERS LLP 3Y 7Y 0.01% Point72 Asset Management, L.P. 3Y 7Y 0.0% INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV 3Y 7Y 0.0%
← Back to GILEAD SCIENCES, INC. Holdings